green valley-wepoker官网

wepoker-微扑克官网-纵横扑克之道
about us
about us
green valley is an innovative chinese pharmaceutical company that pioneers carbohydrate drugs development and manufacturing in the world.
about green valley
our business
mission & vision
our culture
code of business ethics
gv-971
gv-971
here you can get access to more information of gv-971.
products
news reports
research highlights
milestones
scientific research information
scientific research information
originality is the soul of our innovation in scientific research. we are devoted to developing drugs and healthcare solutions that patients are in the greatest need of.
life sciences innovation
research parteners
news
news
here you can get access to the latest news reports of green valley.
press releases
news reports
social responsibility
careers
apart from the competitive compensation & benefits programs, we have developed a detailed benefits and perks scheme. we respect, appreciate and reward the contributions of every employee for their hard work and dedication.
salary and benefits
contact us
contact us
media contacts
wepoker-微扑克官网-纵横扑克之道
news reports
news reports
products
news reports
research highlights
milestones
products
news reports
research highlights
milestones
11-08
2019
science | china approves alzheimer’s drug
11-04
2019
reuters | china gives conditional ok to its first self-developed alzheimer’s drug
11-04
2019
cnn | china approves seaweed-based alzheimer’s drug.it’s the first new one in 17 years
11-04
2019
china daily | alzheimer's drug to go on sale this year
11-04
2019
south china morning post | china approves oligomannate,world’s first new alzheimer’s drug in 20 years and it is based on seaweed
11-04
2019
economics times | china okays sale of first home-grown alzheimer’s drug
11-04
2019
pr newswire | green valley announces nmpa approval of oligomannate for mild to moderate alzheimer’s disease
11-02
2019
green valley announces nmpa approval of oligomannate for mild to moderate alzheimer's disease
shanghai, nov. 2, 2019 /prnewswire/ -- shanghai green valley pharmaceuticals (green valley) today announced that china's national medical products administration (nmpa) has approved oligomannate (gv-971) as new drug for the treatment of "mild to moderate alzheimer's disease (ad) and improving cognitive function."
网站地图